Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GPPB vs Gemcitabine/Cisplatin in Nasopharyngeal Cancer
NCT05305131Phase 2Recruiting
- Sponsor
- National University Hospital
- Start
- Mar 2022
- Primary completion
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, bevacizumab in nasopharyngeal carcinoma (NPC), sponsored by National University Hospital. Started Mar 2022; status: recruiting.
02
Drugs
pembrolizumabbevacizumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT05305131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05305131.